Literature DB >> 23329596

The authors' reply to Allen et al.: "A Comment on Boyers et al.: 'eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal'".

Dwayne Boyers, Xueli Jia, David Jenkinson, Graham Mowatt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23329596     DOI： 10.1007/s40273-012-0005-6

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  2 in total

Review 1.  Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal.

Authors:  Dwayne Boyers; Xueli Jia; David Jenkinson; Graham Mowatt
Journal:  Pharmacoeconomics       Date:  2012-06-01       Impact factor: 4.981

2.  A comment on Boyers et al.: "eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal".

Authors:  Rachel Allen; Andres Brainsky; Kelly Grotzinger; Tito Roccia
Journal:  Pharmacoeconomics       Date:  2013-01       Impact factor: 4.981
  2 in total
  5 in total

Review 1.  Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal.

Authors:  Huiqin Yang; Dawn Craig; David Epstein; Laura Bojke; Kate Light; Ian N Bruce; Mark Sculpher; Nerys Woolacott
Journal:  Pharmacoeconomics       Date:  2012-04       Impact factor: 4.981

Review 2.  Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery: a NICE single technology appraisal.

Authors:  Michael Holmes; Christopher Carroll; Diana Papaioannou
Journal:  Pharmacoeconomics       Date:  2012-02-01       Impact factor: 4.981

Review 3.  Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal.

Authors:  Claire McKenna; Emma Maund; Muhammad Sarowar; David Fox; Matt Stevenson; Chris Pepper; Nerys Woolacott; Stephen Palmer
Journal:  Pharmacoeconomics       Date:  2012-01       Impact factor: 4.981

4.  Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal.

Authors:  Rumona Dickson; Adrian Bagust; Angela Boland; Michaela Blundell; Helen Davis; Yenal Dundar; Juliet Hockenhull; Carlos Martin Saborido; James Oyee; Vidhya Sagar Ramani
Journal:  Pharmacoeconomics       Date:  2011-12       Impact factor: 4.981

Review 5.  Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal.

Authors:  Graham Scotland; Norman Waugh; Pamela Royle; Paul McNamee; Rob Henderson; Rosemary Hollick
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.